Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline M Tanner

Showing results (161-170 of 207) with videos related to

Pageof 21
Sort By:
Movement Disorders Clinical Practice|June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyDaniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
JAMA Neurology|August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseJu-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2019
A specific amino acid motif of <i>HLA-DRB1</i> mediates risk and interacts with smoking history in Parkinson's diseaseJill A Hollenbach, Paul J Norman, Lisa E Creary, et al.
Environmental Health Perspectives|January 29, 2011
Rotenone, paraquat, and Parkinson's diseaseCaroline M Tanner, Freya Kamel, G Webster Ross, et al.
JMIR Research Protocols|August 27, 2025
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational StudyAudrey Hoyt, Casey Dorney, Peggy Auinger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
Nature Biotechnology|August 10, 2021
Remote smartphone monitoring of Parkinson's disease and individual response to therapyLarsson Omberg, Elias Chaibub Neto, Thanneer M Perumal, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Neurology. Clinical Practice|August 26, 2017
Virtual visits for Parkinson disease: A multicenter noncontrolled cohortRyan E Korn, Aparna Wagle Shukla, Maya Katz, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Pageof 21

Showing results (161-170 of 207) with videos related to

Sort By:
Pageof 21
Movement Disorders Clinical Practice|June 19, 2023
Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory StudyDaniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, et al.
JAMA Neurology|August 28, 2013
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson diseaseJu-Hee Kang, David J Irwin, Alice S Chen-Plotkin, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 27, 2019
A specific amino acid motif of <i>HLA-DRB1</i> mediates risk and interacts with smoking history in Parkinson's diseaseJill A Hollenbach, Paul J Norman, Lisa E Creary, et al.
Environmental Health Perspectives|January 29, 2011
Rotenone, paraquat, and Parkinson's diseaseCaroline M Tanner, Freya Kamel, G Webster Ross, et al.
JMIR Research Protocols|August 27, 2025
Improving Prediction of Falls and Cognitive Impairment in Parkinson Disease: Protocol for a Decentralized Observational StudyAudrey Hoyt, Casey Dorney, Peggy Auinger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
Nature Biotechnology|August 10, 2021
Remote smartphone monitoring of Parkinson's disease and individual response to therapyLarsson Omberg, Elias Chaibub Neto, Thanneer M Perumal, et al.
Annals of Neurology|May 14, 2026
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers InitiativeEthan G Brown, Lana M Chahine, Roseanne D Dobkin, et al.
Neurology. Clinical Practice|August 26, 2017
Virtual visits for Parkinson disease: A multicenter noncontrolled cohortRyan E Korn, Aparna Wagle Shukla, Maya Katz, et al.
Annals of Neurology|December 25, 2024
Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein DiseaseEthan G Brown, Lana M Chahine, Andrew Siderowf, et al.
Pageof 21